IQVIA has an 88% higher success rate for Phase II and 25% higher for Phase III across Inflammatory Bowel Disease (IBD) trials as compared to industry rates.
Having run more than 50 phase II and III IBD trials since 2017, we manage the challenges of operational delivery every day. Competition for sites and patients is intense, and patient-reported outcomes and endoscopy must ultimately demonstrate clear efficacy for approval.
Years of experience have enabled us to build a repository of data, best practices, and research to continuously improve IBD clinical development. Performance data from more than 40 trials in the last five years power site identification. New technology improves the quality of patient reported outcomes. And advancements in endoscopy algorithms obtain higher separation between placebo and active treatment.